Timber Pharmaceuticals Inc Quick Ratio (TMBR) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Timber Pharmaceuticals Inc   (NYSE: TMBR)

Timber Pharmaceuticals Inc 's Quick Ratio

TMBR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2023, Quick Ratio fell to 0.45 below Timber Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 490 other companies have achieved higher Quick Ratio than Timber Pharmaceuticals Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 1935 to 2907.

Explain Quick Ratio?
How much Cash & cash equivalents TMBR´s has?
What are TMBR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TMBR Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change -14.42 % 19.43 % 20.26 % 193.72 % 236.25 %
Y / Y Cash & cash equivalent Change -69.55 % -62.66 % -45.98 % 234.34 % 34.99 %
Quick Ratio MRQ 0.45 1.11 1.8 2.24 1.26
TMBR's Total Ranking # 2907 # 1935 # 1524 # 1423 # 1816
Seq. Current Liabilities Change 20.5 % -7.41 % 0.84 % -23.93 % 68.16 %
Seq. Cash & cash equivalent Change -51.32 % -43 % -19.1 % 35.66 % -40.31 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 491
Healthcare Sector # 925
Overall Market # 2907


Quick Ratio Statistics
High Average Low
12.09 1.86 0
(Jun 30 2020)   (Sep 30 2013)




Financial Statements
Timber Pharmaceuticals Inc 's Current Liabilities $ 6 Millions Visit TMBR's Balance sheet
Timber Pharmaceuticals Inc 's Cash & cash equivalent $ 3 Millions Visit TMBR's Balance sheet
Source of TMBR's Sales Visit TMBR's Sales by Geography


Cumulative Timber Pharmaceuticals Inc 's Quick Ratio

TMBR's Quick Ratio for the trailling 12 Months

TMBR Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 24.17 % 81.01 % 130.45 % 234.75 % 3.04 %
Y / Y Cash & cash equivalent TTM Growth -33.81 % -15.94 % 21.97 % 77.05 % 14.29 %
Quick Ratio TTM 1.38 1.59 2.07 2.55 2.58
Total Ranking TTM # 4057 # 4020 # 3980 # 3948 # 1079
Seq. Current Liabilities TTM Growth -4.45 % 3.7 % 4.32 % 20.14 % 39.28 %
Seq. Cash & cash equivalent TTM Growth -17.05 % -20.46 % -15.4 % 18.6 % 5.34 %

Quick ratio ranking by company, industry and sector >> Back to TMBR Financial Strength Comparisons >> Go to Compare TMBR Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in TMBR's Current Liabilities to $5.62 millions, cumulative Quick Ratio to 1.38 below the TMBR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 544 other companies have achieved higher Quick Ratio than Timber Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 4020 to 4057.

Explain Quick Ratio?
How much Cash & cash equivalents TMBR´s has?
What are TMBR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 545
Healthcare Sector # 1097
Within the Market # 4057


trailing twelve months Quick Ratio Statistics
High Average Low
4.06 1.9 0.67
(Sep 30 2021)   (Jan 31 2017)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Mustang Bio inc   1.23 $ 15.385  Millions$ 12.530  Millions
Enlivex Therapeutics Ltd  1.22 $ 36.060  Millions$ 29.492  Millions
Ainos Inc   1.22 $ 1.361  Millions$ 1.114  Millions
Unicycive Therapeutics Inc  1.22 $ 18.818  Millions$ 15.419  Millions
Novo Nordisk A  1.21 $ 3,163.529  Millions$ 2,608.364  Millions
Organogenesis Holdings Inc   1.21 $ 88.917  Millions$ 73.455  Millions
Scorpius Holdings inc   1.21 $ 18.563  Millions$ 15.341  Millions
Scisparc Ltd  1.21 $ 2.081  Millions$ 1.724  Millions
Biodexa Pharmaceuticals Plc  1.15 $ 6.393  Millions$ 5.569  Millions
Summit Therapeutics Inc   1.13 $ 10.645  Millions$ 9.450  Millions
Lifevantage Corp  1.10 $ 21.605  Millions$ 19.609  Millions
Sonnet Biotherapeutics Holdings Inc   1.09 $ 7.021  Millions$ 6.466  Millions
Apexigen Inc   1.07 $ 9.369  Millions$ 8.743  Millions
Cns Pharmaceuticals Inc   1.07 $ 4.279  Millions$ 3.997  Millions
Effector Therapeutics Inc   1.05 $ 25.019  Millions$ 23.759  Millions
Transcode Therapeutics Inc   1.05 $ 3.684  Millions$ 3.523  Millions
Reshape Lifesciences Inc  1.04 $ 4.567  Millions$ 4.404  Millions
Calliditas Therapeutics Ab  1.04 $ 104.676  Millions$ 100.997  Millions
Sellas Life Sciences Group Inc   1.04 $ 13.907  Millions$ 13.421  Millions
Spyre Therapeutics Inc   1.01 $ 235.358  Millions$ 232.234  Millions
Xeris Biopharma Holdings Inc   1.01 $ 80.668  Millions$ 79.678  Millions
Evolus Inc   1.01 $ 41.705  Millions$ 41.349  Millions
Avadel Pharmaceuticals Plc  0.99 $ 50.417  Millions$ 50.719  Millions
Inflarx N V  0.98 $ 18.547  Millions$ 18.866  Millions
Nature s Sunshine Products inc   0.97 $ 68.970  Millions$ 71.011  Millions
Zoetis Inc   0.97 $ 1,717.000  Millions$ 1,769.000  Millions
Petros Pharmaceuticals inc   0.96 $ 7.400  Millions$ 7.685  Millions
Therapeuticsmd Inc   0.96 $ 13.729  Millions$ 14.364  Millions
Igc Pharma Inc   0.92 $ 1.950  Millions$ 2.131  Millions
Contrafect Corporation  0.91 $ 14.422  Millions$ 15.796  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.